DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
LY2140023 is an investigational drug.
There have been 23 clinical trials for LY2140023. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.
The most common disease conditions in clinical trials are Schizophrenia, Stress Disorders, Traumatic, and Stress Disorders, Post-Traumatic. The leading clinical trial sponsors are Eli Lilly and Company, New York State Psychiatric Institute, and National Institute of Mental Health (NIMH).
Recent Clinical Trials for LY2140023
|Glutamate Reducing Interventions in Schizophrenia||National Institute of Mental Health (NIMH)||Phase 1|
|Glutamate Reducing Interventions in Schizophrenia||New York State Psychiatric Institute||Phase 1|
|Pomaglumetad Effects on Glutamate Biomarkers||National Institute of Mental Health (NIMH)||Phase 1|